Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The OR for achieving a weight loss of at least 5% with tirzepatide 5 mg, 10 mg and 15 mg (vs GLP-1 RAs) was, respectively, 1.96 (95% CI 1.01, 3.80 [ I 2 61%]), 4.79 (95% CI 1.95, 11.73 [ I 2 74%]) and 4.57 (95% CI 3.38, 6.18 [ I 2 0%]) (ESM Table 2)
A 2.5mg dose requires 0.15mL
A.SternbergJ
Table of Contents How MASLD Presents Beyond Traditional Risk Factors Why GLP1s Are Gaining Attention in Liver Disease Recognizing Lean Liver Disease in Clinical Practice Integrating GLP1s into a LiverFirst Treatment Strategy Evidence Summary: What the Data Suggest Practical Considerations for Clinicians How MASLD Presents Beyond Traditional Risk Factors MASLD encompasses a spectrum from simple steatosis to inflammatory and fibrotic disease (NASH)
US$ 29.57
US$ 22.97
US$ 24.15
US$ 22.90
